General information about company

Scrip code*544709
NSE Symbol*GAUDIUMIVF
MSEI Symbol*NOTLISTED
ISIN*INE0P8B01020
Name of companyGAUDIUM IVF AND WOMEN HEALTH LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved18-03-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange12-03-2026
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterThird quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year endedUnaudited
Segment ReportingSingle segment
Description of single segmentHealth Care Business
Start date and time of board meeting18-03-2026 16:15
End date and time of board meeting18-03-2026 18:05
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?NoNo default on loans and hence it is not applicable



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations1419.354941.25
Other income10.332.15
Total income1429.654973.4
2Expenses
(a)Cost of materials consumed00
(b)Purchases of stock-in-trade133.52364.33
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade-3.16-9.63
(d)Employee benefit expense 206.87569.36
(e)Finance costs112.26212.57
(f)Depreciation, depletion and amortisation expense46.66182.81
(g)Other Expenses
1Cost of rendering services227.67625.3
2Other expenses271.241061.45
Total other expenses498.911686.75
Total expenses995.063006.19
3Total profit before exceptional items and tax434.591967.21
4Exceptional items 00
5Total profit before tax434.591967.21
6Tax expense
7Current tax121.89515.18
8Deferred tax-5.7-3.61
9Total tax expenses116.19511.57
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations318.41455.64
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method00
16Total profit (loss) for period318.41455.64
17Other comprehensive income net of taxes1.935.79
18Total Comprehensive Income for the period320.331461.43
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital3069.723069.72
Face value of equity share capital55
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations0.522.38
Diluted earnings (loss) per share from continuing operations0.522.38
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations0.522.38
Diluted earnings (loss) per share from continuing and discontinued operations0.522.38
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)Notes to Statement of Unaudited Standalone Financial Results
1.The unaudited standalone financial results for the quarter and nine months ended 31 December 2025 ('the results') of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of Companies Act, 2013 ('The Act') read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.The operating segment of the Company is identified as "Health Care Business", as the Chief Operating Decision Maker reviews business performance at an overall company level as one segment. Therefore, the disclosure as per Regulation 33(1)(e) read with Clause (L) of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.
3.The results have been reviewed and recommended by the Audit Committee of the Board and approved by the Board of Directors on 18 March 2026.
4.The Statutory Auditors of the Company have carried out a limited review of the unaudited standalone financial results for the quarter and nine months ended 31 December 2025 and have issued an unmodified Review Report. The Review Report of the Statutory Auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Ltd ('BSE') and is also available on the Company's website.
5.The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes, collectively referred to as the “New Labour Codes”. These Codes, inter alia, introduce a revised definition of “Wages” for the purpose of computation of various employee benefits.
The Company has evaluated the potential impact of the revised definition of wages on its employee benefit obligations. Considering that the Company already structures employee compensation in accordance with the revised definition of wages under the New Labour Codes is not expected to have a material impact on the computation of employee benefits such as gratuity and compensated absences.
Accordingly, no additional liability or past service cost has been recognised in the financial results for the quarter and nine months ended 31 December 2025. The Company will continue to monitor developments relating to the implementation of the New Labour Codes and will reassess the impact, if any, upon notification of the final rules.
6.Subsequent to quarter ended 31 December 2025, the Company’s has completed Initial Public Offering (IPO) of 2,08,86,200 equity shares of face value Rs. 5 each at an issue price of Rs. 79 per share aggregating to Rs. 16,500.098 Lakhs (it includes estimated offer expenses) and comprising offer for sale of 94,93,700 equity shares aggregating amounting to Rs. 7,500.023 Lakhs (it includes estimated offer expenses). Pursuant to IPO, the equity shares were listed on the NSE and BSE on 27th February 2026.
7.The figures for the corresponding previous periods have been regrouped / reclassified wherever necessary to conform to the current period presentation, and such regrouping does not have any impact on profit / loss of the Company.
8.Item of expenditure which exceeds 10% of the total expenditure
Advertising fees for the quater ended December 2025 is 126.72 lakhs , for quarter ended 30 September 2025 is 154.33 lakhs, for the quarter ended 31 december 2024 is 146.50 lakhs, for the nine months ended 31 December 2025 is 441.44 lakhs , for the nine months ended 31 December 2024 is 390.16 lakhs and for the year ended 31 March 2025 is 560.82



Other Comprehensive Income

Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1 -Items that will not be reclassified to profit or loss2.587.74
Total Amount of items that will not be reclassified to profit and loss2.587.74
2Income tax relating to items that will not be reclassified to profit or loss 0.651.95
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss
5Total Other comprehensive income1.935.79